A22.0 Cutaneous anthrax

Name of the Condition

• Cutaneous anthrax (ICD-10-CM Code: A22.0)

Summary

Cutaneous anthrax is a localized bacterial infection of the skin caused by Bacillus anthracis. It is the most common form of anthrax and typically results from direct contact with contaminated animal products or spores. The condition progresses through distinct stages, starting with a painless lesion and potentially leading to systemic involvement if untreated. Prompt medical care is essential to prevent complications.

Causes

Cutaneous anthrax is caused by the spore-forming bacterium Bacillus anthracis. Infection occurs when spores enter the skin through cuts, abrasions, or other breaks in the skin barrier, often from handling infected animals, hides, wool, or contaminated materials. Spores can remain viable in the environment for years, enabling exposure even after the initial source is no longer active.

Risk Factors

• Occupational exposure to livestock or animal byproducts (e.g., farmers, veterinarians, tannery workers).
• Handling or processing animal hides, wool, or bone meal from endemic regions.
• Contact with contaminated soil or animal remains in areas with known anthrax outbreaks.
• Limited access to protective measures during high-risk activities.

Symptoms

• Initial: Painless, raised bump or papule at the site of exposure, often resembling an insect bite.
• Progression: Ulceration with a characteristic black eschar (scab) surrounded by swelling and redness.
• Systemic: Fever, malaise, and regional lymph node enlargement may develop as the infection advances.

Diagnosis

Diagnosis is confirmed through clinical evaluation of the characteristic skin lesion and laboratory testing. Samples from the lesion (e.g., swabs, tissue) are cultured to identify Bacillus anthracis, and molecular assays (e.g., PCR) may be used for rapid detection. Blood tests may be performed if systemic spread is suspected.

Treatment Options

• Antibiotics: Oral or intravenous antibiotics (e.g., ciprofloxacin, doxycycline) are the primary treatment, typically administered for 7–10 days.
• Wound care: Lesions are kept clean and covered to prevent secondary infection.
• Supportive care: Pain management and monitoring for signs of systemic involvement are standard.

Prognosis and Follow-Up

With early treatment, prognosis is excellent, and most patients recover fully. Untreated cases may progress to severe systemic infection or sepsis. Follow-up appointments ensure complete resolution of the lesion and monitor for recurrence or complications.

Complications

• Secondary bacterial infection of the skin lesion.
• Systemic spread (sepsis) if left untreated.
• Rarely, meningitis or other organ involvement in advanced cases.

Lifestyle & Prevention

• Avoid contact with sick or dead animals, especially in endemic areas.
• Use protective gloves and clothing when handling animal products.
• Practice good wound hygiene to reduce infection risk.
• Seek medical evaluation for suspicious skin lesions after potential exposure.

When to Seek Professional Help

Consult a healthcare provider immediately if you develop a painless ulcer with a black center, especially after handling animals or animal products, or if you experience fever, swelling, or systemic symptoms.

Tips for Medical Coders

Document the site of the lesion (e.g., arm, face) and any associated symptoms (e.g., fever, lymphadenopathy) to support code assignment. Ensure the diagnosis is clearly linked to exposure history or laboratory confirmation. Code A22.0 is specific to cutaneous anthrax and should not be used for other anthrax forms.